Thu, Dec 25, 2014, 7:30 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • golongin2008 golongin2008 May 22, 2013 7:13 PM Flag

    Gram Negative Bacteria

    I'm sure some of you saw the release by GSK today about the US funding of 200 million in research and development costs to held advance new antibiotics to replace those that have become partially or totally resistant to current antibiotics such as PFE's Zyvox, as well as other bio terrorism threats.

    So the question to the group is...How how does Tedizoli shape up vis-a-vis Zyvox in treating these
    antibiotic resistant bacterias, and next, could it be effective on gram negative bacterias, or is the company in development of such an antibiotic?

    TIA...Long and Strong TSRX!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Trius Therapeutics has a cooperative research and development agreement with Lawrence Livermore National Security LLC for researching and developing gram-negative biodefense pathogens; a research agreement with UCSD for jointly researching antibacterial agents for combating gram-negative and gram-positive biodefense pathogens; a research contract with Lawrence Livermore National Laboratory for the development of antibiotics directed against gram negative multi-drug resistant bacterial pathogens

    • the entire purpose of the GAIN act was to encourage and expedite approval of gram positive antibiotics such as Tedizolid. So far Tedizolid phosphate was shown to be best in it's class and an alternative to linezolid for treating ABSSS. Further indications studies for blood and pneumonia infections will follow later this year. Being a bactericide makes Ted even more effective in killing the bacteria rather than slowing it down as many other antibiotics have in the past encouraging the development of resistant strains. Ted is effective against MRSA.
      GyrB/ParE, which are under preclinical program and are targets of the fluoroquinolone (wide spectrum)class of antibacterial agents, such as ciprofloxacin are used to treat gram +ve Streptococcus pneumonia. I don't know of any gram negative agents (bio-terrorism) TRSX is working on to date. But it might be all hush, hush like SIGA. (8=3) Hope this helps.

      • 3 Replies to beavertail_splash
      • GAIN Act covers both +ve &-ve gram bacterial antibiotic development.

      • BEAV, you've lost me on this. Did you read the TSRX website about the broad spectrum activity in the funded project. The goal is to hit gram negatives and strains resistant to current class (ie Cipro). Read from pipeline description on TSRX website:

        "As our lead compounds are dual-targeting, inhibiting both GyrB and ParE, we expect that they will be active against fluoroquinolone-resistant strains of bacteria. We believe that the key advantages of inhibiting both targets include an expected low rate of emergence of bacterial resistance and increased potency. Moreover, the compounds that we have identified in our GyrB/ParE program have broad antibacterial spectrum.
        In our research funded by NIAID, we are focused on developing agents directed to the gram-negative spectrum that include bacteria important for biodefense purposes. Antibiotics active against these biodefense targets often have cross activity against clinically important gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae and Escherichia coli. Consequently, compounds developed under our NIAID contract should also have significant utility in treating infections caused by these clinically important bacteria, such as respiratory tract, urinary tract and intra-abdominal infections. With resistance to current drug classes (including carbapenems and fluoroquinolones) growing rapidly among gram-negative bacteria, we believe treatment for these infections is a significant unmet medical need. Our NIAID contract supports the GyrB/ParE program for biodefense purposes through Phase 1 clinical trials, subject to the achievement of program milestones."

        Look up the data on slide shows and you will see what differentiates this from existing treatments.

      • Beaver...Much thanks, and it does help in knowing the spectrum of R&D that TSRX is involved in.
        I really like this one as much as I hate Siga...LOL...Uunfortunately, I drank the Siga Kool Aide at the high so you know where that ended up. Maybe you can make a killing on Siga at current levels, but I have little faith in management, or the reported on "pipeline" they portend to be developing.

        PS...In the GSK release today they mentioned that development of new antibiotics to replace
        current ones which are becoming resilient to certain bacterias has been slow to evolve because
        of the lack of large monetary recovery for the time, effort and expenses involved in development
        of such new antibiotics.

        As an owner of TSRX I was quite encouraged by that statement. I mean...We're already there.
        Cheaper to buy us for $20 it would seem then start from scratch or throw money at some project where the outcome is uncertain..

        GL to you and GLTAL's here!

    • Sounds like you need to do some DD. Tons of presentation and posters to read on TSRX website. Way too much to write. Short answer is yes we can kill bugs that may be resistant to Zyvox. TED is more potent. TED can be used with Cubist antibiotic to kill some nasty gram negatives. We also have a pipeline compound funded with US grant money to kill a ton of bugs and maybe can help with terrorism threats. GSK may want to buy us with the $200 million. JMO

      Sentiment: Strong Buy

 
TSRX
13.630.0000(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST